Ordena

Cercar

Barra de cerca
01/10/2023 On the relevance of thrombomodulin variants in atypical hemolytic uremic syndrome
Huerta A., Arjona E., Portoles J., Lopez-Sanchez P., Cavero T., Fernandez-Cusicanqui J., Blasco M., Cabello V., Calvo N., Diaz M., Herrero-Goñi M., Aguirre M., Elías S., Alcaide M.P., Ramos N., Sellares J., Rodríguez de Córdoba S.. On the relevance of thrombomodulin variants in atypical hemolytic uremic syndrome. KIDNEY INTERNATIONAL. 2023; 104(4)DOI:10.1016/j.kint.2023.07.020. PMID:37567446. IF:14.800(Q1/1D).
29/09/2023 Treatment and long-term outcome in primary nephrogenic diabetes insipidus
Lopez-Garcia, SC, Downie, ML, Kim, JS, Boyer, O, Walsh, SB, Nijenhuis, T, Papizh, S, Yadav, P, Reynolds, B, Decramer, S, Besouw, M, Carrascosa, MP, La Scola, C, Trepiccione, F, Ariceta, G, Hummel, A, Dossier, C, Sayer, JA, Konrad, M, Keijzer-Veen, MG, Awan, A, Basu, B, Chauveau, D, Madariaga, L, Koster-Kamphuis, L, Furlano, M, Zacchia, M, Marzuillo, P, Tse, Y, Dursun, I, Pinarbasi, AS, Tramma, D, Hoorn, EJ, Gokce, I, Nicholls, K, Eid, LA, Sartz, L, Riordan, M, Hooman, N, Printza, N, Bonny, O, Sancho, PA, Schild, R, Sinha, R, Guarino, S, Jimenez, VM, Peña, LR, Belge, H, Devuyst, O, Wlodkowski, T, Emma, F, Levtchenko, E, Knoers, NVAM, Bichet, DG, Schaefer, F, Kleta, R, European NDI Consortium, Bockenhauer, D. Treatment and long-term outcome in primary nephrogenic diabetes insipidus. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2023; 38(10)DOI:10.1093/ndt/gfaa243. PMID:33367818. IF:4.800(Q1/2D).
26/09/2023 Polygenic risk of major depressive disorder as a risk factor for venous thromboembolism.
Ward J, Le NQ, Suryakant S, Brody JA, Amouyel P, Boland A, Bown R, Cullen B, Debette S, Deleuze JF, Emmerich J, Graham N, Germain M, Anderson JJ, Pell JP, Lyall DM, Lyall LM, Smith DJ, Wiggins KL, Soria JM, Souto JC, Morange PE, Smith NL, Trégouët DA, Sabater-Lleal M, Strawbridge RJ. Polygenic risk of major depressive disorder as a risk factor for venous thromboembolism.. Blood Advances. 2023; 7(18)DOI:10.1182/bloodadvances.2023010562. PMID:37399490. IF:7.400(Q1/2D).
26/09/2023 Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.
Moreno C, Solman IG, Tam CS, Grigg A, Scarfò L, Kipps TJ, Srinivasan S, Mali RS, Zhou C, Dean JP, Szafer-Glusman E, Choi M. Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.. Blood Advances. 2023; 7(18)DOI:10.1182/bloodadvances.2023010236. PMID:37315225. IF:7.400(Q1/2D).